Zepbound supply has tripled since launch and is still constrained. The manufacturing footprint now represents one of the strongest competitive moats in large-cap pharma.
The Mounjaro and Zepbound franchise generated approximately $24 billion of revenue in 2024 and is on track for $38 billion in 2025. Demand continues to exceed supply despite aggressive capacity expansion. The critical question for the next five years is not demand; it is how much supply Lilly can bring online.
The Research Desk view: Lilly has extended the manufacturing lead over Novo Nordisk to a 12 to 18-month advantage and is building capacity that Novo cannot match in the near term. The competitive dynamic has shifted from product to production.
Lilly has committed more than $30 billion to GLP-1 manufacturing capacity expansion since 2022. New facilities in Indiana, North Carolina, Ireland, and Germany are in various stages of construction and qualification. The Research Triangle facility alone will add capacity for hundreds of millions of incremental annual doses.
Fill-finish capacity is the tightest constraint in the supply chain. Lilly's acquisition of Nexus Pharmaceuticals' Pleasant Prairie facility in 2024 and the expansion at the Research Triangle campus have materially eased that bottleneck. By late 2026, fill-finish capacity should no longer be the limiting factor.
API production capacity is the next constraint. Lilly's investments in Kinsale and the Research Triangle API lines address this, with meaningful incremental capacity coming online through 2026 and 2027.
TickerXray Report
Get the complete Eli Lilly report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Novo Nordisk has also been aggressive on capex, but the gap is real and durable.
Novo's capacity buildout has been constrained by several operational issues, including compliance events at its Catalent acquisitions. The ramp of its newer facilities has been slower than management targeted. Lilly's comparable ramp has been materially faster.
Product differentiation favours Lilly on efficacy for weight loss. Tirzepatide (Mounjaro/Zepbound) produces higher mean weight loss than semaglutide (Wegovy/Ozempic) at comparable doses, and that clinical advantage is now supported by multiple phase 3 readouts.
Oral formulations are the next differentiator. Lilly's oral GLP-1 candidate orforglipron is in late-stage trials and produced weight loss results comparable to injectable tirzepatide in phase 2. Oral Novo's oral semaglutide shows smaller effect sizes.
Together, these factors suggest Lilly maintains the category leadership for at least another three years, and potentially through the decade.
Tirzepatide product gross margin is estimated in the high 80s percent range. Operating margin on the incretin franchise is lower than the gross margin due to ongoing clinical trial spend and manufacturing ramp costs, but is tracking above 50% at scale.
Price per dose net of rebates has compressed somewhat as Medicare Part D and PBM contracts have been renegotiated in 2024 to 2025. The compression has been more than offset by volume growth.
Compounding risk. The GLP-1 shortage has driven significant volume through compounding pharmacies, selling product at a fraction of list price. The FDA's November 2024 and subsequent actions have begun to constrain compounding as shortages ease, which should tighten realised pricing in 2025 to 2026.
Lilly's broader metabolic pipeline extends the franchise beyond tirzepatide.
Retatrutide is a GLP-1/GIP/glucagon triple agonist that produces weight loss in the 24 to 28% range in phase 2, substantially higher than tirzepatide. Phase 3 readouts are expected through 2026.
Orforglipron, the oral GLP-1, addresses the injection friction barrier and could meaningfully expand the patient population.
The diabetes franchise, which pre-dated the GLP-1 wave, continues to contribute meaningful profits via Trulicity, Jardiance (partnered with Boehringer), and the insulin portfolio.
Four catalysts.
Manufacturing capacity unlocks. Each new facility coming online is a step-function increase in addressable demand.
Orforglipron readouts. Phase 3 data through 2025 to 2026 determine the size of the oral GLP-1 opportunity.
Retatrutide approval timeline. Phase 3 data expected late 2025 to early 2026. If positive, this becomes Lilly's next mega-blockbuster.
Medicare Part D coverage. Political pressure for broader Medicare GLP-1 coverage has been building. Any move toward coverage is a multi-billion-dollar revenue catalyst.
Phase 3 failure on orforglipron or retatrutide. Either would meaningfully reduce the long-duration growth profile.
Medicare price negotiation expansion. The Inflation Reduction Act's price negotiation process could target GLP-1s starting in 2028 or 2029, compressing realised pricing on Medicare volumes.
Manufacturing incident. A compliance or quality event at a major facility could compress supply growth.
Competitive threat from Amgen, Roche, or Chinese biotechs. Several phase 2 readouts from these players are expected through 2026 and could reset competitive intensity.
Lilly at 38x forward earnings is rich by historical standards, but the growth profile is unprecedented in large-cap pharma. Fair value on 2027 EPS estimates of $32 at a 32x multiple is approximately $1,024. Bull case $1,200 if retatrutide data disappoints to the upside. Bear case $720 on a Medicare pricing shock or phase 3 setback.
We are buyers on any pullback below $800. Conviction is high on the manufacturing-led thesis and rising on the pipeline.
Full forensic analysis of Eli Lilly
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Lilly's revenue compounded 56% in the most recent quarter on a $30+ billion run-rate. The GLP-1 cycle is the most consequential pharmaceutical event since the statin era. The data behind the thesis.
LLY trades at the lowest forward multiple in 18 months while net income has compounded from $5.2B in FY2023 to $20.6B in FY2025. The earnings line is running 2-3 quarters ahead of the multiple.
LLY trades at 26.7x forward on GLP-1 growth. MRK trades at 22x forward on a Keytruda cliff. The Valuation Desk compares the two franchises on durability, pipeline, and execution to identify the next leg of pharma outperformance.